Literature DB >> 1714562

HP 0.35, a cephalosporin degradation product is a specific inhibitor of lentiviral RNAses H.

P Hafkemeyer1, K Neftel, R Hobi, A Pfaltz, H Lutz, K Lüthi, F Focher, S Spadari, U Hübscher.   

Abstract

Penicillins, cephalosporins and other betalactam antibiotics are widely used antibacterial drugs. Recently it was found that some of them also have effects on proliferating eukaryotic cells (Neftel, K.A. and Hübscher, U. (1987) Antimicrob. Agents Chemother. 31, 1657-1661), and one such effect was shown to be the inhibition of DNA polymerase alpha (Huynh Do,U., Neftel, K.A., Spadari, S. and Hübscher, U. (1987) Nucl. Acids Res. 15, 10495-10506). The data suggested that degradation products of betalactam antibiotics were responsible for the inhibitory effect on DNA polymerase alpha. There is some confirmation at the structural level, since we found that penicillin binding proteins, the natural target of the cephalosporins, share amino-acid homologies to DNA polymerases and also to reverse transcriptase from HIV1 (Hafkemeyer, P., Neftel, K.A. and Hübscher, U. Meth. Find. Exp. Clin. Pharmacol. 12, 43-46, 1990). We have purified and determined the structure of one product from the cephalosporin Ceftazidim and found one molecule (HP 0.35) that did not interfere with eukaryotic cell proliferation but rather had a specific inhibitory effect on the RNase H activity of human immunodeficiency virus 1 (HIV1) and feline immunodeficiency virus (FIV) reverse transcriptases, while the DNA polymerising activity of these enzymes was not affected. RNases H from HeLa cells, calf thymus and Escherichia coli on the other hand were much less affected by HP 0.35. The inhibitory concentration of 50% (IC50) was more than 10 times lower compared to those of all cellular RNases H. We therefore tested the effect of HP 0.35 on in vitro lentivirus infection as exemplified by FIV-infection of CD(4+)-cat lymphocytes in cell culture. Under conditions where cell proliferation was absolutely unaffected, HP 0.35 was able to inhibit FIV-infection in CD(4+)-cat lymphocytes. Moreover, preincubation of these lymphocytes with HP 0.35 rendered the cells completely unsusceptible to FIV-infection. These data suggest that a degradation product of a clinically used betalactam antibiotic might represent an effective inhibitor class for lentiviral RNase H.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1714562      PMCID: PMC328541          DOI: 10.1093/nar/19.15.4059

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  31 in total

1.  Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses.

Authors:  R A Olmsted; V M Hirsch; R H Purcell; P R Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

2.  Revised nomenclature for eukaryotic DNA polymerases.

Authors:  P M Burgers; R A Bambara; J L Campbell; L M Chang; K M Downey; U Hübscher; M Y Lee; S M Linn; A G So; S Spadari
Journal:  Eur J Biochem       Date:  1990-08-17

Review 3.  Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides.

Authors:  R Yarchoan; H Mitsuya; C E Myers; S Broder
Journal:  N Engl J Med       Date:  1989-09-14       Impact factor: 91.245

4.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

5.  Specificity assessment of feline T-lymphotropic lentivirus serology.

Authors:  H Lutz; P Arnold; U Hübscher; H Egberink; N Pedersen; M C Horzinek
Journal:  Zentralbl Veterinarmed B       Date:  1988-12

Review 6.  Effects of beta-lactam antibiotics on proliferating eucaryotic cells.

Authors:  K A Neftel; U Hübscher
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

7.  Inhibition of granulopoiesis in vivo and in vitro by beta-lactam antibiotics.

Authors:  K A Neftel; S P Hauser; M R Müller
Journal:  J Infect Dis       Date:  1985-07       Impact factor: 5.226

8.  Molecular cloning of feline immunodeficiency virus.

Authors:  R A Olmsted; A K Barnes; J K Yamamoto; V M Hirsch; R H Purcell; P R Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

9.  Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome.

Authors:  N C Pedersen; E W Ho; M L Brown; J K Yamamoto
Journal:  Science       Date:  1987-02-13       Impact factor: 47.728

10.  Identification and characterization of HIV-specific RNase H by monoclonal antibody.

Authors:  J Hansen; T Schulze; W Mellert; K Moelling
Journal:  EMBO J       Date:  1988-01       Impact factor: 11.598

View more
  3 in total

Review 1.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

2.  The amphiphilic properties of novenamines determine their activity as inhibitors of HIV-1 RNase H.

Authors:  I W Althaus; K M Franks; K B Langley; F J Kézdy; T Peterson; S E Buxser; D E Decker; L A Dolak; R G Ulrich; F Reusser
Journal:  Experientia       Date:  1996-04-15

Review 3.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.

Authors:  M Bendinelli; M Pistello; S Lombardi; A Poli; C Garzelli; D Matteucci; L Ceccherini-Nelli; G Malvaldi; F Tozzini
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.